Browse Articles

Discover research articles across all indexed journals

Prognostic significance of PSA in the outcomes of patients with high risk localized prostate cancer.

Journal of Clinical Oncology Mohammad Arfat Ganiyani, Atulya Aman Khosla, Pushan Prabhakar et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.347

347 Background: Patients diagnosed with localized high-risk prostate adenocarcinoma (LHRPC) with high Gleason scores (8-10) and prostate-specific antigen (PSA) levels ≤ 4 may experience an altered clinical course. In these patients, low PSA levels may reflect cellular dedifferentiation, indicating more aggressive tumor behavior despite appearing to have a low disease burden. We aim to investigate the impact of PSA levels in patients with LHRPC to better understand prognosis and optimize treatment strategies. Methods: We included patients diagnosed with LHRPC based on TNM stage (T1-T4, N0, M0) and Gleason 8–10 from 2004 to 2020, using data from the National Cancer Database. We stratified patients based on PSA levels (≤4 and >4 ng/dl) and treatment approaches. We utilized Kaplan-Meier analysis and Cox proportional hazard model to study survival outcomes in patients with LHRPC. Results: We included 160,971 patients diagnosed with LHRPC, of which 86.69% (139,546) had PSA >4 ng/dl, while only 13.31% (21,425) had PSA ≤4 ng/dl. Our cohort had 69.55% (111,953) patients aged ≥ 65 years and 30.45% (49,018) aged < 65 years. Regarding race, the cohort was predominantly white, comprising 81.69% (131,497), followed by black at 14.47% (23,292), and other racial categories at 3.84% (6,182). In our cohort 34.43% (55,425) underwent surgery only (S), 9.62% (15,484) received radiation therapy only (RT), 46.81% (75,350) had radiation therapy combined with androgen deprivation therapy (RT + ADT), and 9.14% (14,712) received androgen deprivation therapy only (ADT). In our multivariate cox proportional hazard analysis, LHRPC patients with PSA >4 ng/dL had a 7% (HR 0.93, 95% CI: 0.90–0.95; p<0.001) decreased risk of death compared to those with PSA ≤4 ng/dL. Conclusions: In our study, LHRPC patients with PSA ≤4 ng/dL had poorer survival outcomes after adjusting for the treatment approach, race, age category, income, insurance status, facility type, and location. Further research is required to explore potential biological differences in patients with low PSA-secreting LHRPC. Cox proportional hazard analysis in patients with LHRPC, GS 8-10. Categories Hazard Ratio (95% CI) P-value Treatment type: Surgery only reference RT only 2.27 (2.19, 2.36) <0.001 RT + ADT 2.37 (2.30, 2.44) <0.001 ADT only 5.68 (5.49, 5.87) <0.001 Charlson Deyson score : 0 reference >=1 1.43 (1.40, 1.46) <0.001 Facility type : Academic reference Non-Academic 1.20 (1.17, 1.23) <0.001 PSA ≤ 4 ng/dl reference PSA > 4 ng/dl 0.93 (0.90, 0.95) <0.001

Real-world clinical practice gaps in timely homologous recombination repair gene mutation (HRRm) testing and poly (ADP-ribose) polymerase inhibitor (PARPi) treatment of patients with metastatic castration resistant prostate cancer (mCRPC).

Journal of Clinical Oncology Neal D. Shore, Anupama Vasudevan, John Li et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.85

85 Background: Testing for HRRm is standard of care for all mCRPC patients to identify those eligible to receive PARPi targeted therapy. Our previous real-world analysis of testing and treatment patterns (1/1/2020 – 12/31/2021) revealed 40.8% of mCRPC patients did not receive HRRm testing while 33.2% of HRRm positive (HRRm+) patients did not receive a PARPi. The approval of novel hormonal therapies (NHT) in combination with PARPi for first line treatment of mCRPC prompted us to expand our analysis, to determine timing of HRRm testing in relation to line of therapy (LOT) initiated, LOT when NHT and/or PARPi were received, and breakdown of HRRm+ genes in PARPi treated and untreated cohorts. Methods: The IntegraConnect – Precision Q de-identified database that includes electronic health and practice management data from 500 US sites of care was utilized to select a real-world cohort of newly diagnosed or treated mCRPC patients between 1/1/2020 - 12/31/2023. Patient charts were manually reviewed by medical curators to extract data including frequency and timing of germline and somatic testing for HRRm, testing success rate and results, and LOT where NHT and/or PARPi were received in the HRRm+ cohort. Results: Of the 1022 mCRPC total patients, 63.6% (n=650) received HRRm testing [21.2% germline (n=138); 58.8% somatic (n=382); 3.4% (n=22) germline + somatic; 16.6% (n=108) unknown]. Timing of HRRm testing revealed 19% (n=122) were tested at time of diagnosis, 41% (n=265) during or after first LOT, 22% (n=145) during or after second LOT, and 18% (n=118) at 3+ LOT. Only 9% (n=56) of patients had testing failures with 38% (n=21) originating from somatic tissue testing. Of the 38% (n=226) of HRRm+ patients, 58.4% (n=132) received a PARPi, including 13 patients receiving PARPi in >1 LOT and 23% (n=33) receiving PARPi/NHA combination therapy. 65% (n=95) of patients received PARPi therapy after >3 LOT. The HRRm+ genes in the PARPi treated cohort included BRCA2 (33.6%; n=51), ATM (30.9%; n=47), CHEK2 (13.2%; n=20), BRCA1 & CDK12 (6.6%; n=10), PALB2 (5.3%; n=8), RAD54L (2%; n=3), BRIP1 , CHEK1 , & RAD51B (0.7%; n=1). Of the 94 patients who did not receive PARPi therapy, 15.9% (n=17), 29% (n=31) and 3.7% (n=4) were BRCA2 , ATM , and BRCA1 mutation positive, respectively. Conclusions: This extended real-world analysis confirms clinical practice gaps with HRRm testing and receipt of matched PARPi therapy in mCRPC. 81% of patients do not receive HRRm testing at the time of mCRPC diagnosis and only 35% of HRRm+ patients receive PARPi prior to third LOT. It is particularly concerning that not all BRCA1/2 and ATM positive patients receive PARPi therapy. Continuing education and standardized testing practices may be needed to address these gaps.

Universal scaling of electrostatic effects of a curved counter-electrode on the emitter field enhancement

Applied Physics Letters Thiago A. de Assis, Fernando F. Dall'Agnol Feb 10, 2025 DOI: 10.1063/5.0252449

Experiments on field electron emission from single-tip nanoemitters have typically been carried out using a counter-electrode with a finite curvature radius R, positioned at a distance dgap from the emitter's apex. The effects of the counter-electrode's curvature on the apex field enhancement factor (γCa) of the emitter are still not understood. In this Letter, we theoretically explore how the apex field enhancement factor of an emitter, represented by a hemisphere on a cylindrical post (HCP) with apex radius ra=50 nm, is influenced by the curvature of a sphere-shaped counter-electrode. Importantly, our results show that for HCPs with sharpness aspect ratios typically between 102 and 103, there is a universal scaling such that γCa=γPaΨ(R/dgap), where γPa represents the apex field enhancement factor for the emitter assuming a planar counter-electrode, and Ψ(R/dgap) is a universal scaling function such that Ψ∼1 for R/dgap≫1 and Ψ∼(R/dgap)α, with α close to unity, for R/dgap≪1. These findings help partially explain discrepancies observed in orthodox field electron emission experiments, where it was reported that the effective γCa values extracted from the current–voltage characteristics of single-tip carbon nanotubes typically underestimate the theoretical γPa values when R∼dgap≫ra, a trend that is predicted by our results.

Genetic characterization and phylogenetic analysis of common house crows (Corvus splendens)

Scientific Reports Muhammad Arbab Khan, Muhammad Latif, Muhammad Mansha et al. Feb 10, 2025 DOI: 10.1038/s41598-025-85207-8

Efficacy outcomes 12 months after initiation of darolutamide in non-metastatic castrate resistant prostate cancer (nmCRPC) from the real world UK multi-centre RECORD study.

Journal of Clinical Oncology Amarnath Challapalli, Amit Bahl, Manreet Randhawa et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.83

83 Background: Darolutamide has authorisation for treatment of non-metastatic Castrate Resistant Prostate Cancer (nmCRPC) based on the ARAMIS trial. The RECORD Study is a prospective real-world evaluation (RWE) of clinical outcomes in patients with nmCRPC treated with darolutamide in the UK. The study will improve understanding of treatment response and duration as well as inform regarding the use of next generation imaging (NGI) and effects of concomitant medication. Methods: Patients were enrolled from 19 centres over a 3-year period from November 2020. Data cut-off was 16 September 2024. Disease characteristics of patients and efficacy up to 12 months (m) after initiation of darolutamide are evaluated. Descriptive statistics will be used for patient demographics. Results: 257 patients were analysed with a median age of 77 (range 52-94) years (y). 52% have a Gleason score ≥8. 30 patients (11.7%) had NGI prior to initiation of darolutamide and 41 (15.8%) were on anticoagulant/antiplatelet medication. ECOG 0:35%, 1:59% and 2:6.2%. Median pre-treatment PSA was 9.7ng/mL and pre-treatment PSA doubling time (PSAdT) was 5 months. The greatest reduction in median PSA values was seen within the first 3m on darolutamide but was still decreasing slightly at 12m. PSA response was as follows: PSA 50 reduction at 3, 6, 9 and 12 months was 74%, 77%, 75% and 73% respectively and PSA 90 reduction at 3, 6, 9 and 12 months was 28%, 38%, 43% and 42% respectively. No differential effect on PSA reduction was seen with Gleason score (<8, ≥8), PSAdT≤6m or >6m, previous treatment (RT or prostatectomy), anticoagulant/antiplatelet medication or those who had NGI. Median duration of treatment on darolutamide did not significantly differ (p=0.067) in patients with PSAdT>6m (104 patients) compared to those with PSAdT≤6m (135 patients). 46 patients (17.9%) have come off treatment within 12m of initiation: 26 (10.1%) disease progression, 8 (3.1%) toxicity (most frequent being fatigue and diarrhoea), 12 other unrelated causes including 1 death. Conclusions: This RWE shows that patients with nmCRPC in clinical practice have comparable outcomes to the ARAMIS trial. Response rates, tolerability and discontinuation rates are similar and in particular only 3.1% discontinuing treatment due to toxicity. Gleason score >8; PSAdT and the use of NGI had no differential impact on PSA response. This is valuable RWE enabling optimisation of treatment in nmCRPC.

Survival disparities by sex with contemporary advanced urothelial carcinoma (aUC) therapy: A real-world analysis.

Journal of Clinical Oncology Adam Barsouk, Omar Elghawy, Jonathan Henry Sussman et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.670

670 Background: Retrospective population data suggest poorer survival for female aUC patients. However, data on survival disparities in the era of immuno- and targeted therapies is limited. Methods: This cohort study used Flatiron Health’s nationwide de-identified electronic health record (EHR)-derived database. 7,244 patients (pts) were identified. Patients started on systemic therapy for aUC from 1/1/2017 to 5/1/2024, with reported sex, were included. Baseline demographics (including social determinants of health (SDOH) score), Eastern Cooperative Oncology Group performance status (ECOG PS), disease characteristics, treatment history, and clinical outcomes were abstracted. Progression free survival (PFS) and overall survival (OS) were compared between male and female patients, via Kaplan-Meier log-rank analysis and Cox proportional hazards models that included race, gender, and first-line therapy. Independent sample t-tests and chi-square analyses were used for univariate comparisons. P-values < 0.05 were considered statistically significant. Results: A total of 3,045 pts with aUC were identified. 762 were (25.0%) female. In 1L, 28% received immunotherapy (IO) monotherapy, 3.4% received enfortumab vedotin+pembrolizumab (EVP), 37% received carboplatin (carbo), 28% cisplatin (cis), and 6% other chemotherapy (p=0.814). Females were more like to have ECOG PS>1 at diagnosis (p=0.020). Greater SDOH score was not associated with sex (p>0.1). Female sex was associated with inferior 1L PFS (median 4.3 vs 4.6m; HR 1.14, p=0.04) but no difference in OS (6.4 vs 6.5m; HR 1.01, p=0.2). Females had inferior PFS to men on Cox multivariable analysis when adjusting for race and first line therapy (p=0.006). On Cox univariate analysis stratified by 1L treatment, PFS was comparable between sexes on carbo (n=1127; p=0.4), cis (n=856; p=0.2) and EVP (n=25, p= 0.7), but women had inferior PFS to men on IO (n=595, p= 0.01). Women had comparable OS to men among all 1L treatments. Conclusions: In a large real-world database, female aUC patients had inferior PFS but comparable OS to males. Among 1L treatments, only immunotherapy was associated with inferior PFS for females vs. males. Baseline characteristics and survival in males vs. females. Male (n=2283) Female (n=762) Sig (p) Baseline Characteristics ECOG PS 0-1 (%) 64.1 60.6 0.020 2-4 (%) 15.2 17.8 Treatment at Academic Center (%) 19.1 18.0 0.360 SDOH score 3.13 3.07 0.110 1L Treatment IO (%) 27.7 28.1 0.814 EVP (%) 3.3 3.7 Carbo (%) 37.3 36.2 Cis (%) 27.5 28.9 Other (%) 6.6 6.1 Survival mPFS (m) 4.6 4.3 0.040 mOS (m) 6.5 6.4 0.200 Sig. values in bold (p<0.05).

A phase 1b study of cabozantinib and nivolumab with abiraterone (CABIOS) in metastatic castration-sensitive prostate cancer (mCSPC): Updated safety, efficacy, and immunologic findings.

Journal of Clinical Oncology Parker Mathews, Muhammad Azeem Saeed, Jesse Meir Zaretsky et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.186

186 Background: Standard of care for mCSPC typically includes androgen deprivation (ADT) with novel hormonal agents +/- docetaxel. CABIOS is a phase Ib single-arm trial of cabozantinib + nivolumab + abiraterone/prednisone (cabo, nivo, abi/pred) in mCSPC (NCT04477512). Preliminary safety and efficacy data were previously reported. Methods: Eligible patients (pts) had de novo or recurrent mHSPC with < 12 weeks ADT prior to enrollment, ECOG 0-1, and adequate end organ function. Further details on trial design were previously reported. The primary endpoint is safety and tolerability. Secondary endpoints include overall survival (OS), progression free survival (PFS), PSA response, and failure-free survival (FFS; defined as any one of clinical, PSA, or radiographic progression, or new treatment start). Exploratory analyses include CyTOF of peripheral blood and multiplex serum cytokine ELISA. Results: The trial is closed to accrual. 18 pts enrolled between 2/2021 and 3/2023 received treatment and are included in the analysis. Median follow-up is 32 months. There were no dose-limiting toxicities (DLTs). Gr 3-4 treatment related adverse events (TRAEs) occurred in 8 pts. The most common serious TRAEs were AST/ALT elevation (4), diarrhea (3), and hypertension (3). Treatment continued for or beyond study duration (two years) in 6 pts. Treatment was stopped in 12 pts due to adverse events (6), progression (5), and patient preference (1). Median OS and PSA PFS have not been reached. Nine of 18 pts had an FFS event at a median of 15.6 months compared with a median censored FFS of 32.2 months to-date in the remaining pts. CyTOF analyses of peripheral blood revealed a significant increase in effector cytotoxic CD8+ T-cells, total NK cells and CD16 hi cytotoxic NK cells post- compared with pre-treatment. Conversely, regulatory CD4+ and CD8+ T-cell as well as Th17 cell populations were significantly decreased in peripheral blood post-treatment. Furthermore, a marked reduction in free-active TGF-β and soluble LAG3 were observed in serum post vs. pre-treatment. We compared pre-to-post fold changes in these populations between patients who have and have not experienced treatment failure (FFS). Early treatment failure was associated with reduced innate lymphoid cells and increased total B-cells. Conclusions: Here, we present updated clinical and immune correlative findings of the first trial of cabozantinib in combination with nivolumab in mCSPC patients receiving ADT and abi/pred. Overall, the trial showed acceptable safety/tolerability with no DLTs. Grade 3+ TRAEs were seen in 44% of patients. Correlative data suggest a favorable peripheral immunomodulation by the treatment combination with a reduction in suppressive soluble factors and increase in effector immune populations. Future studies will evaluate the tumor microenvironment. Clinical trial information: NCT04477512 .

Impact of Medicare Advantage (MA) on timely hormonal intensification in metastatic hormone sensitive prostate cancer.

Journal of Clinical Oncology Baqir Jafry, Chuan Angel Lu, Jonathan Wenbin Ji et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.166

166 Background: As MA plans gain popularity, covering over half of eligible beneficiaries in 2023, concerns have arisen about their ability to manage complex cancer care due to pre-authorization requirements and limited physician networks. The study compares MA and Traditional Medicare (TM) in delivering timely hormonal intensification, specifically through addition of oral novel hormonal therapy (NHT) to castration therapy, which became central part of treating metastatic hormone-sensitive prostate cancer (mHSPC) by 2018. Methods: We utilized nationwide Flatiron Health Electronic Health Record-derived de-identified database to include patients diagnosed with mHSPC on or after 2018 (when abiraterone was approved for mHSPC treatment). Eligible patients were >=65 yr old, had at least one clinic visit within six months of diagnosis, and were covered by either MA or TM. Multivariable logistic regression with Inverse Probability Weighting, adjusting for socioeconomic status (SES), age, race, ECOG, and year of diagnosis, assessed the impact of insurance type on likelihood of initiating NHT within 30, 45, and 90 days of diagnosis (defined as date when the patient began taking prescribed NHT, within the period of interest). Results: 4078 patients >=65 yr old diagnosed with mHSPC after 2018 were identified in Flatiron database; of these 2261 had at least one clinic visit and were enrolled in either MA or TM plans. Most patients were White, aged 75-85, having better SES (SES 4 or 5), de novo mHSPC, and from community hospitals (Table 1). Among the 1752 (77%) patients who received NHT, 1060 (61%) had TM, and 692 (39%) had MA. In adjusted analysis, TM patients were more likely than MA patients to initiate timely NHT intensification within 45 days of mHSPC diagnosis (OR: 0.85; 95% CI: 0.74-0.99). No significant differences were found for NHT initiation at 30 (OR: 0.88; 95% CI: 0.74-1.06) or 90 days (OR: 1.06; 95% CI: 0.93-1.22). Subgroup analyses showed significantly more delays in MA compared to TM among patients with lowest SES and racial minorities. Conclusions: Patients with TM showed a trend toward earlier NHT intensification compared to those with MA. This suggests a need to further examine MA and its impact of pre-authorization and network limitations on equitable high quality cancer care. Key baseline characteristics and outcome comparisons between mHSPC patients enrolled in TA and MA. TA N (%) MA N (%) P Race Asian 21 (2%) 13 (2%) <0.001 Black 91 (7%) 91 (10%) Hispanic/Latino 39 (3%) 49 (6%) White 932 (67%) 527 (60%) Other 299 (22%) 199 (23%) ECOG 0/1 958 (69%) 635 (72%) 0.11 2 125 (9%) 69 (8%) 3/4 23 (2%) 23 (3%) Unknown 276 (20%) 152 (17%) SES 1 147 (11%) 113 (13%) <0.001 2 209 (15%) 167 (19%) 3 248 (18%) 189 (22%) 4 347 (25%) 198 (23%) 5 316 (23%) 149 (17%) Unknown 115 (8%) 63 (7%) Initiation of Hormonal Intensification OR (95 CI) P 30 days 1* 0.88 (0.74 - 1.06) 0.18 45 days 1* 0.85 (0.74 - 0.99) 0.04 90 days 1* 1.06 (0.93 - 1.22) 0.37 *Reference.

Enhanced piezoelectricity in TiSXY monolayers based on electronegative polar moments effect

Applied Physics Letters Dai-Song Tang, Yu-Qing Luo, Dan-Yang Zhu et al. Feb 10, 2025 DOI: 10.1063/5.0251468

It is a challenge to find the relationship between the microscopic property of atoms in monolayers and the macroscopic piezoelectricity of monolayer. By first-principles calculation, we find not only the super-dipole moment (SDM) effect but also the electronegative polar moments (EPMs) effect, which can lead to the remarkable piezoelectricity in TiSXY monolayers. The SDM and EPM effects can deepen the understanding of the piezoelectric physical mechanism and provide the design strategy for ultrathin nano-devices.

Identifying invasiveness to aid lung adenocarcinoma diagnosis using deep learning and pathomics

Scientific Reports Hai Du, Xiulin Wang, Kaifeng Wang et al. Feb 10, 2025 DOI: 10.1038/s41598-025-87094-5

Association between PD-1 expression on tumor-infiltrating regulatory T cells and resistance to first-line nivolumab in advanced clear cell renal cell carcinoma: Insights from the HCRN GU16-260 clinical trial.

Journal of Clinical Oncology Razan Mohanna, Berkay Simsek, Nourhan El Ahmar et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.590

590 Background: Inhibition of PD-1 signaling in regulatory T cells (Tregs) has been shown to enhance their immunosuppressive function. We previously demonstrated that high levels of PD-1 expression on tumor-infiltrating Tregs are associated with resistance to nivolumab (nivo) monotherapy in pretreated patients with advanced clear cell renal cell carcinoma (ccRCC) from the CheckMate-025 trial (Denize et al, 2024). Here, we aim to validate these findings in the first-line setting. Methods: Primary tumor tissues from patients with ccRCC (n=70) treated with first-line nivo in the HCRN GU16-260 clinical trial were analyzed using multiparametric immunofluorescence (IF). The percentage of tumor-infiltrating PD-1+ Tregs was quantified by image analysis. Associations with objective response rate (ORR) and progression-free survival (PFS) were evaluated using logistic and Cox regression models, along with Fisher’s exact test and log-rank test for statistical inference, as appropriate. The alpha level was set at 5% (one-sided). Results: In line with our previous findings, the percentage of PD-1+ Tregs, measured as a continuous variable, did not have a statistically significant association with PFS [HR = 2.62; p = 0.169] or ORR [OR = 0.72; p = 0.42]. Using an optimized cut-off based on the minimal p-value for ORR, patients with a high percentage (≥36%) of PD-1+ Tregs (8/70) experienced shorter median PFS (3.4 vs. 10.9 months; p = 0.001) and a trend toward lower ORR (12.5% vs. 43.6%; p = 0.093) compared to those with a low percentage (62/70). Conclusions: PD-1 expression on tumor-infiltrating Tregs is associated with worse outcomes to first-line nivo therapy in patients with advanced ccRCC, confirming our previous findings. These results highlight the therapeutic potential of targeting Tregs to overcome resistance and improve the efficacy of PD-1 blockade, which is currently being evaluated in a clinical trial (HCRN GU22-587).

Impaired renal function and cisplatin-based regimens as risk factors for neoadjuvant chemotherapy-induced acute kidney injury in muscle-invasive bladder cancer: A multicenter retrospective study.

Journal of Clinical Oncology Naoki Fujita, Shogo Hosogoe, Toshikazu Tanaka et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.760

760 Background: Neoadjuvant chemotherapy (NAC)-induced acute kidney injury (AKI) is one of the frequent complications in patients with muscle-invasive bladder cancer (MIBC) and we previously have reported the negative impact of NAC-induced AKI on oncological outcomes. However, its risk factors remain unclear. Methods: This multi-institutional retrospective study included 517 patients with MIBC who received 2–4 cycles of NAC followed by radical cystectomy. AKI was defined according to the KDIGO criteria. Patients were divided into two groups: patients who developed any stage AKI during NAC (AKI group) and patients who did not (non-AKI group). Multivariable logistic regression analysis was performed to identify the risk factors for NAC-induced AKI. The predictive abilities for AKI were evaluated using the area under the receiver operating characteristic (ROC) curve. Results: The median age was 69 years. Of the 517 patients, 188 (36%) received cisplatin-based regimens and 92 (18%) developed any stage AKI. Approximately 86% AKI were stage 1 AKI. eGFR in the AKI group was significantly lower than that in the non-AKI group ( P <0.001). The rate of AKI development in patients who received cisplatin-based regimens was significantly higher than that in patients who received carboplatin-based regimens ( P <0.001). In the multivariable analysis, hypertension, impaired renal function, and cisplatin-based regimen were independently and significantly associated with increased risk of AKI (Table). The optimal cutoff value of estimated glomerular filtration rate for AKI was 65.0 mL/min/1.73m 2 . ROC analysis showed that the area under the curve (AUC) of hypertension plus eGFR <65.0 mL/min/1.73m 2 plus cisplatin-based regimen was 0.748 (95% confidence interval: 0.697–0.799). Conclusions: Hypertension, impaired renal function, and cisplatin-based regimens were risk factors for NAC-induced AKI in patients with MIBC. Multivariable analysis for AKI development. Factor P value Odds ratio 95% CI Age Continuous 0.462 0.989 0.959–1.019 Hypertension Presence 0.016 1.894 1.128–3.179 eGFR Continuous <0.001 0.955 0.939–0.971 Cisplatin-based regimens Positive <0.001 6.530 3.725–11.45

Reply to: Optimizing DeepHRD Interpretability for Enhanced Clinical Decision Making

Journal of Clinical Oncology Erik N. Bergstrom, Scott M. Lippman, Ludmil B. Alexandrov Feb 10, 2025 DOI: 10.1200/jco-24-02279

Real-world U.S. county-level analysis of erectile dysfunction diagnosis following radiation therapy for localized prostate cancer: The impact of rectal spacer utilization.

Journal of Clinical Oncology Ryan Hankins, Ryoko Sato, Parthiv Mehta et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.365

365 Background: Rectal spacers have been shown to reduce side effects of prostate radiotherapy (RT) in prostate cancer (PCa) patients in clinical studies. While rectal spacing may help preserve sexual function after RT, this association has not been explored in large-scale real-world data. This study evaluated the association between rectal spacer use and the prevalence of erectile dysfunction diagnosis among PCa patients receiving prostate RT at the U.S. county level. Methods: This study utilized Medicare 5% and 100% Standard Analytic Files to analyze county-level data. The population consisted of adult PCa patients receiving RT (IMRT, brachytherapy, SBRT, or proton therapy) between 2015 and 2022. The primary outcome was the county-level proportion of patients diagnosed with erectile dysfunction in any year between 2016 and 2023. The primary explanatory variable was the proportion of patients treated with RT using rectal spacer 1 to 5 years before erectile dysfunction diagnosis. Zero-inflated Poisson regression models assessed the association between rectal spacer use and erectile dysfunction diagnosis at county level, controlling for county-level PCa patients characteristics (average age and racial composition) and general population characteristics (median age, racial composition, and median household income). State-level fixed accounted for regional variation. Data for the general population were obtained from the Agency for Healthcare Research and Quality Social Determinants of Health Database 2020. Results: The study included 247,250 PCa patients receiving prostate RT during the study period across 3,132 U.S. counties. The average annual prevalence of erectile dysfunction diagnosis among PCa patients receiving RT at the county level was 1.3%. The proportion of patients receiving rectal spacers increased from 2.9% to 18.9% over the study period. After adjusting for confounders, counties with higher rectal spacer use 4-5 years prior had a significantly lower prevalence of erectile dysfunction diagnosis. A 10-percentage point increase in rectal spacer usage at the county level was associated with a 7.7% reduction in erectile dysfunction diagnosis after 4 years (p<0.001) and an 8.4% reduction after 5 years (p=0.006). Conclusions: In this first assessment of a real-world dataset, the county-level analysis suggests that increased use of rectal spacing among PCa patients receiving prostate RT is associated with a significantly lower prevalence of erectile dysfunction, with a time lag of 4 to 5 years. This finding supports the long-term benefit of rectal spacing in preserving sexual function in PCa patients undergoing prostate RT. Future research should evaluate the etiology of the longer than expected time lag between utilization and benefit.

Light-induced enhancement of alternating current poling quality and mechanical quality factor in ferroelectric single crystals

Applied Physics Letters Xinyu Jin, Yu Wang, Xiangda Meng et al. Feb 10, 2025 DOI: 10.1063/5.0251350

Alternating current poling (ACP) and light fields have been studied as domain engineering methods for regulating the domain structures and improving the physical properties of ferroelectric crystals because of their convenience, effectiveness, and economic advantages. In this study, we propose a LACP method (ACP under above-bandgap light illumination), by which the transparency and electro-optic properties of Mn- and Fe-doped KTa1−xNbxO3 single crystals were improved compared with only ACP. Furthermore, the mechanical quality factor (Qm = 538) of the sample poled using the LACP method increased significantly by 206% in contrast to that of the sample poled by the conventional high-temperature direct current poling method. The results reveal that the light-induced reorientation of defect dipoles is responsible for the enhancement of the ACP quality and Qm. This study provides an efficient and fast poling approach to the material design for multifunctional devices.

The effects of experimental conditions on extraction of polyphenols from African Nutmeg peels using NADESs-UAE: a multifactorial modelling technique

Scientific Reports Udodinma Jude Okeke, Matteo Micucci, Dasha Mihaylova et al. Feb 10, 2025 DOI: 10.1038/s41598-025-88233-8

Clinical efficacy of enfortumab vedotin-pembrolizumab (EV-P) in locally advanced (LA) or metastatic urothelial carcinoma (mUC): A real-world retrospective study.

Journal of Clinical Oncology Prateek Jain, Syed Arsalan Ahmed Naqvi, Muhammad Umair Anjum et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.745

745 Background: The combination of EV-P therapy has recently been approved as first-line (1L) therapy for patients with LA/mUC based on the results of the EV-302 trial. Herein, we report the updated results from a cohort of patients with LA/mUC who received EV-P in real world clinical setting. Methods: This retrospective study included patients with LA/mUC (07/2022-08/2024) at the Mayo Clinic who completed at least one cycle of EV-P. The best overall response (BOR) was evaluated using radiographic imaging and was adjudicated as complete response (CR), partial response (PR), stable disease (SD), mixed response (MR), or progressive disease (PD). The median progression-free survival (PFS), defined as the time from treatment initiation to disease progression or death, was estimated using the Kaplan-Meier method. Patients who had not experienced disease progression by their last follow-up were censored for the PFS analysis. Results: A total of 120 patients were included; 79 (65.8%) were males, 41 (34.1%) females, 109 (91%) White, and 119 (99%) were non-Hispanic/Latino. The median age was 72 years (IQR: 65-77). Of these, only 22 (18.3%) had locally advanced disease while the remaining had mUC; 62 (51.6%) had lower tract urothelial carcinoma (LUTC), 36 (30%) had upper tract urothelial carcinoma (UTUC). The median follow-up time was 7.1 months (IQR: 4.93-9.26). In terms of BOR, 56 patients (46.6%) experienced PR, 34 (28.3%) CR, 12 (10%) PD, 7 (5.8%) MR, and 8 (6.6%) experienced SD. 3 (2.5%) patients were not evaluable. The BOR across subgroups, LA and mUC, including LUTC and UTUC, is summarized in the table. Among the responders, the median number of treatment cycles to first response was 3 (IQR: 2.25–4). Within the follow-up, 28 patients (23.3%) experienced eventual radiographic disease progression; death was observed in 25 patients (20.8%). The median PFS was 12.7 months (95% CI: 9.8-NE), and OS was 25.1 months (16.3-NE). Conclusions: In real world setting, the combination of EV-P in LA/mUC demonstrated clinical efficacy compatible with the findings from the EV-302 trial. Our results showed comparable efficacy with EV-P in both UTUC and LUTC, highlighting it's broad therapeutic potential. However, clinical data at longer follow-up is required to fully evaluate overall survival and the durability of response. mUC LA Overall LUTC UTUC Total patients 98 62 36 22 BOR CR 23 (23.4%) 13 (20.9%) 10 (28.5%) 11 (50%) PR 49 (52.6%) 31 (50%) 18 (50%) 7 (31.8%) SD 6 (6.4%) 2 (3.2%) 4 (11.4%) 2 (9.0%) PD 10 (10.7%) 9 (15.5%) 1 (2.8%) 2 (9.0%) MR 7 (7.5%) 5 (8.6%) 2 (5.7%) 0 (0%)

Circulating tumor DNA as a prognostic biomarker to predict retroperitoneal histology in patients undergoing retroperitoneal lymph node dissection.

Journal of Clinical Oncology Parth Thakker, Connor Drake, Jiping Zeng et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.646

646 Background: Serum tumor markers (STM) are used in the management of patients with testicular cancer. However, a proportion have normal STM even with cancer present. Circulating tumor DNA (ctDNA) has shown promise in for detection of persistent disease. We sought to determine the utility of ctDNA for predicting retroperitoneal histology by comparing patients’ retroperitoneal lymph node dissection (RPLND) histology with their pre-operative ctDNA status. Methods: Patients undergoing primary (P-RPLND) or post-chemotherapy (PC-RPLND) from March 2023 to January 2024 had prospectively collected plasma ctDNA assay (Signatera, Natera Inc.) The association between ctDNA and RPLND histology was assessed. Sensitivity (SN), specificity (SP), and positive (PPV) and negative predictive values (NPV) were calculated for ctDNA to detect active cancer or teratoma alone in the RPLND histology. Results: Forty-six patients undergoing RPLND had pre-operative ctDNA collection with a median age of 33.5 (IQR:27-38.8). Plasma was collected on average, 8.6 days pre-operatively. Twenty (43.5%) patients underwent P-RPLND and 26 (56.5%) patients underwent PC-RPLND. ctDNA was positive in 23 (50%) patients. Two patients underwent P-RPLND for stage I disease and both had (-) ctDNA and histology. Eighteen patients underwent P-RPLND for stage II disease. Of these, 16 had active cancer, 1 had pure teratoma, and 1 had negative histology. ctDNA was positive in 15 of these patients all of which were found to have either teratoma or active cancer on pathology. Of the 3 patients with (-) ctDNA, 1 had negative histology, 1 had mixed, teratoma and seminoma, and 1 had pure seminoma. There were 26 patients who had ctDNA drawn prior to PC-RPLND. Of these, 4 had active cancer, 16 had pure teratoma, and 6 had necrosis on final RPLND histology. ctDNA was positive in 8 patients all of whom had either teratoma or active cancer on histology. Of the 18 PC-RPLND patients with a (-) ctDNA test, 1 had active cancer, 11 had teratoma, and 6 had necrosis. There were no false positive tests in the entire cohort. The SN, SP, PPV, and NPV were 85%, 77%, 74%, 87%, respectively for predicting active cancer. These numbers vary by primary or PC-RPLND patients (Table). Conclusions: To our knowledge, this is the first study evaluating test characteristics of ctDNA results in relation to RPLND histology. These findings suggest that ctDNA may be a useful adjunctive screening tool to predict active cancer or teratoma in the RP. Test characteristics of ctDNA stratified by primary or post-chemotherapy RPLND. Sensitivity Specificity PPV NPV P-RPLND GCT and/or Teratoma 88% 100% 100% 60% GCT only 88% 75% 93% 60% Teratoma only 100% 26% 7% 100% PC-RPLND GCT and/or teratoma 40% 100% 100% 33% GCT only 75% 77% 38% 94% Teratoma only 31% 70% 63% 39%

Peak Corticosteroid Dose for Immune-Related Adverse Events and Survival: Not the Whole Story

Journal of Clinical Oncology Deniz Can Guven Feb 10, 2025 DOI: 10.1200/jco-24-01878

Clinical outcomes from a prospective study of comprehensive genomic testing in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology Daniel Shevrin, Mathew Yang, Linda Sabatini et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.216

216 Background: In this prospective study at a community-based hospital, we conducted comprehensive genomic testing to identify pts with actionable variants. We previously showed that this resulted in identification of 38% of pts with a recommendation for treatment, predominantly with a PARP inhibitor (PARPI). We now report on the clinical outcomes of pts who received treatment based on this genomic testing. Methods: Pts with mCRPC had genomic testing with cfDNA using the PredicineCare NGS assay and germline and tissue (archival and metastasis) using the Northshore Expanded Cancer NGS Panel. Repeat cfDNA testing was done in pts when they showed cancer progression. Response to genomic-directed treatment (GDT) was evaluated by clinical or radiographic PFS (crPFS) and > 50% decrease in PSA from baseline (PSA50). Results: Of 138 enrolled pts, all had germline and cfDNA testing. Tumor tissue was obtained in 60 pts (archival 41%, metastasis 46%, both 13%). Repeat cfDNA testing was done in 25% of pts. Overall, 59 pts (43%) had a variant with a treatment recommendation. Testing with cfDNA alone identified 68% of which 28% were repeat. An HRR variant was detected in 57 pts (BRCA2 40%, ATM 14%, CHEK2 21%, CDK12 7%, other 13%). Of the 59 pts, 51% have received a GDT with a PARPI or pembrolizumab. Repeat cfDNA testing identified 27% of these pts. Reasons for no treatment included pts who had not yet received GDT as they were receiving effective treatment or pts with a poor performance status. The median crPFS was 4 months; 95% CI (1-11). There was no difference in PFS between pts with BRCA2 vs non-BRCA2 or repeat vs no repeat testing. A PSA50 was observed in 31% of pts (63% had a BRCA2). There was no difference between pts with BRCA2 vs non-BRCA2 or repeat vs no repeat testing. The median number of treatments for mCRPC prior to GDT was 2; 95% CI (1-6). There was a trend for longer PFS in pts receiving ≤ 2 vs > 2 prior treatments (5.3 vs 3.6 m; p=0.09). Of the pts receiving GDT, 57% had Group 4 or 5 Gleason, 37% had visceral metastasis, and 40% had > 10% weight loss. The median cfDNA fraction was 40.4%. Conclusions: In this prospective study done in a community setting, comprehensive genomic testing resulted in a relatively large number (43%) of pts with a treatment recommendation. Most of these pts (68%) were identified by cfDNA alone that also included repeat testing upon progression. Thus far, half of these pts have received a GDT with treatment available in the future for the others. The short PFS and low PSA50 are likely related to the pts being heavily pretreated and having a high tumor burden. This is expected in pts with late-stage mCRPC and corroborates the value of earlier use of GDT, although treatment in these pts still resulted in clinical benefit. Repeat cfDNA testing helped identify additional pts with a treatment recommendation, but further studies are required to define the validity of this testing.